Injectable for Profile Improvement & Double Chin

KYBELLA®

Improve the look of fuller chins with KYBELLA®, a non-surgical, non-invasive injectable for profile improvement & double chin.

Have you noticed your chin profile sagging or sloping? This sagging—called submemental fullness—can be caused by aging, weight gain, or genetics. Targeting this area with diet and exercise alone is extremely difficult. Now you can reduce the appearance of a double chin with KYBELLA®, an injectable, non-surgical treatment for use on the fat below the chin. 


KYBELLA® is the only FDA-approved injectable treatment that destroys fat cells in the treatment area under the chin to leave you with a sleeker chin profile. The aesthetic specialists at Integrity Health & Wellness will design a treatment plan tailored to your desired outcome.


KYBELLA® may be right for you if:

  • You’re bothered (unhappy, self-conscious, embarrassed) by fat under the chin, also known as submental fullness
  • You feel the condition makes you look older or heavier than you actually are
  • You don’t want to have surgery
  • You eat well and exercise, but submental fullness does not go away


Schedule a consultation today with our aesthetic specialists to learn more!

Real Patients Before & After treatment with Kybella®

logo for Kybella deoxycholic acid injection

Real patient treated with Kybella® shown. Actual results may vary.

Earn Points on Kybella® & more with Allē Rewards!

Did you know that you could be earning points on purchases of BOTOX® Cosmetic, Juvéderm®, and Kybella®? With the new Allē loyalty program (formerly known as Brilliant Distinctions™), you can earn points on your favorite Allergan Aesthetics® brands and a variety of other in-office treatments. Join today to start enjoying rewards, and so much more!

Schedule a Consultation

Get the skin and the body you want now!

logo for CareCredit medical financing
Apply for CareCredit Financing

Check us out on Instagram

Instagram logo
Facebook logo

Important Safety Information for Kybella®

  • IMPORTANT SAFETY INFORMATION — KYBELLA®

    KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information


    INDICATION


    KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.


    The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.


    IMPORTANT SAFETY INFORMATION



    CONTRAINDICATIONS


    KYBELLA® is contraindicated in the presence of infection at the injection sites.


    WARNINGS AND PRECAUTIONS


    Marginal Mandibular Nerve Injury


    Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.


    Dysphagia


    Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.


    Injection-Site Hematoma/Bruising


    In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.


    Risk of Injecting into or in Proximity to Vulnerable Anatomic Structures


    To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles. Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury


    Injection Site Alopecia


    Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.


    Injection Site Ulceration and Necrosis


    Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.


    ADVERSE REACTIONS


    The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.


    Please see KYBELLA® full Prescribing Information.

Share by: